公司于2007年开始销售及分销DHA产品。根据弗若斯特沙利文，公司为中国母婴营养品行业藻油DHA分部的先行者。公司将所售的营养品定位为高端及优质营养品，针对怀孕及产后妇女、婴幼儿至儿童等消费者。尤其公司的藻油DHA产品的主要原材料由藻油原材料供应商（为世界领先的海外供应商）供应且公司将藻油产品的建议零售价定为每颗DHA胶囊人民币4元以上。根据弗若斯特沙利文，就公司的产品的原料来源、零售价及品牌市场定位而言，其可归类为高端营养品。According to the Hong Kong Stock Exchange disclosure on December 29, Newmans Health Food Holdings Co., Ltd. submitted a statement to the main board of the Hong Kong Stock Exchange, with CaiTong International as its sole sponsor.
The Zhitong Finance App learned that according to the Hong Kong Stock Exchange disclosure on December 29, Newmans Health Food Holdings Co., Ltd. submitted a statement to the main board of the Hong Kong Stock Exchange, and Caitong International Finance Co., Ltd. is its sole sponsor.
According to the prospectus, Newmans is mainly engaged in marketing, sales and distribution of finished nutritional products in China. The company's nutritional products are sold under exclusive brands (i.e. “Newmans” and “Newmans” (English “Nemans”)), and can be roughly divided into five main categories, namely algae oil, DHA, probiotics, vitamins, multi-dimensional nutrients, and algae calcium products. The company's business is heavily dependent on the company's brand.
The company began selling and distributing DHA products in 2007. According to Frost & Sullivan, the company is a pioneer in the algal oil DHA division of the Chinese maternal and child nutrition industry. The company positions the nutritional products it sells as high-end and high-quality nutritional products, targeting consumers from pregnant and postpartum women, infants to children. In particular, the main raw materials for the company's algae oil DHA products are supplied by the algae oil raw material supplier (the world's leading overseas supplier), and the company sets the recommended retail price for algae oil products at least RMB 4 per DHA capsule. According to Frost & Sullivan, the company's products can be classified as high-end nutritional products in terms of raw material origin, retail price, and brand market positioning.
Algae oil DHA products are the company's main products and account for a large part of the revenue during the performance period. In fiscal year 2020, fiscal year 2021, fiscal year 2022 and the six months of 2023, the company's sales of algae oil DHA products accounted for about 87.0%, 91.9%, 92.7% and 93.5% of total revenue, respectively. According to Frost & Sullivan, the company's brand is one of the most recognized high-end DHA brands in China in 2022. According to Frost & Sullivan, China's maternal and infant algae oil DHA market can be subdivided into products launched by international and domestic traders. Among them, domestic products can be further divided into products using locally purchased and imported algae oil DHA raw materials. In 2022, domestic brands using imported algae oil DHA raw materials accounted for 27.5% of the total retail value of algae oil DHA products in China, of which the company accounted for about 22.5% in 2022. Based on the total retail value of algae oil DHA products made from imported raw materials, the company is the largest domestic brand. With the success of algae oil DHA products, the company has been marketing other nutritional products such as probiotics, vitamins, multi-nutrients, and seaweed calcium products.
The company strives to provide nutritional products made from high-quality and safe raw materials. In order to monitor product quality, the company requires suppliers of algae oil DHA and probiotic products to use key raw materials provided by algae oil raw material suppliers and probiotic raw material suppliers. The main ingredients concerned will then be processed into the company's finished nutritional products.
On the financial side, the increase in the company's revenue and gross profit during the performance period was mainly due to increased revenue from the sale of algae oil DHA products. For fiscal year 2020, fiscal year 2021, fiscal year 2022 and the six months of 2023, the company's revenue was approximately RMB 242 million, $338 million, $367 million and $192 million, respectively. The company's total gross margin remained relatively stable at around 72.8%, 73.0%, 74.4%, 76.1% and 75.8%, respectively. The company's profit was reduced from approximately RMB 120 million in fiscal year 2021 to approximately RMB 87.522 million in fiscal year 2022, mainly due to non-recurring asset incidental losses of approximately RMB 81.5 million arising from confirmed sales of milk powder products in fiscal year 2022.
